LIXTE Biotechnology Holdings Regains Nasdaq Compliance, Raises $6.5 Million for Cancer Trials

LIXTE Biotechnology Holdings has regained Nasdaq compliance after raising $6.5 million through combined offerings. The company's clinical trials for three cancer indications are progressing, focusing on its lead compound, LB-100, which aims to enhance chemotherapies and immunotherapies for cancer patients.

PASADENA, Calif., July 16, 2025 — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company, has regained compliance with Nasdaq’s Listing Rule 5550(b)(1), the "Equity Rule," which requires a minimum equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market. This compliance was achieved following the closing of a $5.0 million placement and a $1.5 million registered direct offering, announced on July 2, 2025, and July 8, 2025, respectively [1].

Geordan Pursglove, LIXTE’s Chief Executive Officer, commented, "Regaining compliance underscores the Company's dedication to its Nasdaq listing and to fostering LIXTE’s financial health, as it continues to pursue its promising clinical trials in ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma, among other opportunities" [1].

LIXTE Biotechnology Holdings is focused on developing new targets for cancer drug development and commercializing cancer therapies. Its lead compound, LB-100, is a first-in-class clinical PP2A inhibitor that has shown well-tolerated properties in cancer patients at doses associated with anti-cancer activity. LB-100 has the potential to significantly enhance chemotherapies and immunotherapies, improving outcomes for patients with cancer. The company's new approach, covered by a comprehensive patent portfolio, is advancing a new treatment paradigm in cancer biology known as activation lethality [1].

Proof-of-concept clinical trials for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma are currently underway. The company's financial health and compliance with Nasdaq's continued listing requirements are crucial for maintaining investor confidence and supporting its ongoing research and development efforts [1].

References:
[1] https://ir.lixte.com/news-events/press-releases/detail/128/lixte-biotechnology-holdings-regains-compliance-with-nasdaqs-continued-listing-requirements